Letters
Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market
Privia A. Randhawa, Rupinder Brar and Seonaid Nolan
CMAJ January 20, 2020 192 (3) E73; DOI: https://doi.org/10.1503/cmaj.74018
Privia A. Randhawa
Medical student, Department of Medicine, University of British Columbia, Vancouver, BC
BScH MPHRupinder Brar
Family and addictions physician, British Columbia Centre on Substance Use; Department of Medicine, University of British Columbia, Vancouver, BC
MDSeonaid Nolan
Assistant professor, British Columbia Centre on Substance Use; Department of Medicine, University of British Columbia, Vancouver, BC
MDIn this issue
Article tools
Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market
Privia A. Randhawa, Rupinder Brar, Seonaid Nolan
CMAJ Jan 2020, 192 (3) E73; DOI: 10.1503/cmaj.74018
Related Articles
Cited By...
- Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel
- Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl
- Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence